Loading...
Loading...
Color vision testing is a standard component of comprehensive eye examinations. As a paraoptometric, you will administer these screenings to identify patients with color vision deficiencies -- conditions that affect approximately 1 in 12 males and 1 in 200 females. While most congenital color deficiencies are harmless inconveniences, screening serves important purposes: occupational qualification assessment, monitoring for drug-induced toxicity, and detecting acquired conditions that signal retinal or neurological disease.
The most commonly used screening tool is the Ishihara pseudoisochromatic plate test, which you will likely administer hundreds of times during your career. Understanding how these tests work, what they detect, and what they miss is essential knowledge for both the CPO and CPOA exams and for clinical competence.
Color vision is mediated by three types of cone photoreceptors in the retina, each sensitive to a different range of wavelengths: short (S-cones, blue), medium (M-cones, green), and long (L-cones, red). Color deficiency occurs when one or more cone types are absent, reduced in number, or have altered spectral sensitivity. The type and severity of deficiency depends on which cones are affected and to what degree.
Color deficiencies are classified by which cone type is affected. The terminology uses Greek roots: protos (first, for red/long-wavelength cones), deuteros (second, for green/medium-wavelength cones), and tritos (third, for blue/short-wavelength cones). Each type can range from anomalous (reduced function) to absent (anopia).
Affects the L-cones (long wavelength, red-sensitive). Protanomaly is reduced red sensitivity; protanopia is absent red cones entirely. Patients confuse reds, oranges, and greens. A distinctive feature of protan deficiency is darkening of the red end of the spectrum -- reds appear unusually dark, which can be a safety concern (red traffic signals, brake lights).
Affects the M-cones (medium wavelength, green-sensitive). The most common form of color deficiency by far. Deuteranomaly is the single most prevalent type, affecting about 5% of all males. Patients confuse similar colors as protan individuals (reds, greens, oranges) but without the darkening of the red spectrum. Deuteranopia is complete absence of M-cones.
Affects the S-cones (short wavelength, blue-sensitive). Congenital tritan deficiency is extremely rare (about 1 in 10,000-50,000). However, acquired tritan deficiency is clinically significant because it occurs with certain medications (ethambutol, hydroxychloroquine), cataracts (which absorb blue light), and retinal diseases. Patients confuse blues with greens and yellows with violets.
Inheritance Pattern
Red-green deficiencies (protan and deutan) are X-linked recessive. A mother who is a carrier (one normal X, one affected X) has a 50% chance of passing the defective gene to each son. Her daughters will be carriers but rarely affected. This explains the dramatic sex difference in prevalence. Tritan deficiency, by contrast, is autosomal dominant and affects males and females equally.
The Ishihara test is the most widely used color vision screening tool worldwide and the one you are most likely to encounter in clinical practice and on certification exams. Designed by Dr. Shinobu Ishihara in 1917, it uses plates composed of colored dots arranged so that a number or path is visible to individuals with normal color vision but invisible (or a different number is seen) to those with red-green deficiency.
The plates work on the principle of pseudoisochromatic confusion. The dots that form the number and those that form the background are carefully chosen to have the same brightness (luminance) but different colors. A person with normal color vision sees the color difference and reads the number. A person with red-green deficiency cannot distinguish the dots by color and either sees nothing, a different number, or a different path through the dots.
Demonstration plate (Plate 1)
Visible to everyone, including color-deficient individuals. Used to confirm the patient understands the task. If a patient cannot read this plate, the problem is not color vision -- it may be visual acuity, literacy, or comprehension.
Transformation plates
Show one number to color-normal individuals and a different number to color-deficient individuals. Useful for confirming the presence of a deficiency.
Vanishing plates
Show a number to color-normal individuals that is invisible to color-deficient individuals. The most common type in the test booklet.
Hidden digit plates
Show a number that is visible only to color-deficient individuals. Normal observers see no number. Useful for detecting malingering.
Tracing plates (for illiterate patients or children)
Winding paths instead of numbers. The patient traces the path with their finger. Essential for testing young children or patients who cannot read numbers.
Use natural daylight or a daylight-balanced bulb (illuminant C or D65, approximately 6500K color temperature). Fluorescent or incandescent lighting changes the apparent colors on the plates and can produce false results. If your testing room has only fluorescent lights, consider a dedicated task lamp with a daylight bulb for color testing.
Hold the plates at 14-16 inches from the patient, perpendicular to the line of sight (not tilted). The plates should be right-side up. Test with near correction in place if the patient normally wears it, as this is a near task. Test each eye separately, then both eyes together.
Patients should respond within 3 seconds. Longer viewing times allow tracing strategies and brightness-based discrimination that can compensate for color deficiency, producing a falsely normal result. Ask the patient to respond quickly with their first impression. Present plates in order.
Record the patient's response for each plate. Score according to the test manual -- typically, missing a threshold number of plates (often 4 or more errors out of the screening plates) indicates a deficiency. Note specific plates missed, as the pattern can differentiate protan from deutan deficiency. Document the number of plates administered and the number correct.
The HRR test uses pseudoisochromatic plates similar to Ishihara but screens for all three deficiency types, including blue-yellow (tritan). The test includes screening plates to detect any deficiency and diagnostic plates that grade severity as mild, medium, or strong. HRR is particularly valuable for monitoring acquired color vision changes from medications or disease because acquired deficits often affect the blue-yellow axis first.
An arrangement test with 15 colored caps that the patient must place in chromatic order. The pattern of errors reveals the type and severity of deficiency. The D-15 is not a screening test -- it is used to assess the functional significance of a known deficiency. A patient who makes major crossings on the D-15 has moderate-to-severe deficiency that may affect daily tasks. Minor errors suggest mild deficiency.
The gold standard for detailed color vision assessment. Contains 85 color caps (despite the name) arranged in four boxes. The patient orders them by color sequence. Error scores are plotted on a circular diagram that reveals the type, axis, and severity of deficiency. This test is too time-consuming for routine screening (20-30 minutes) but is used in research, occupational testing, and detailed clinical evaluation.
Color vision screening serves several distinct clinical purposes. Understanding these helps you appreciate why the test is included in comprehensive examinations and why proper technique matters.
Many occupations require normal color vision: pilots, electricians (wire colors), train engineers, law enforcement, firefighters, and certain military roles. Documentation of color vision status is often required for employment.
Medications like ethambutol (tuberculosis), hydroxychloroquine (autoimmune diseases), and digoxin (heart failure) can cause acquired color vision loss. Regular screening detects toxicity early, before permanent damage occurs. Blue-yellow loss is often the first sign.
Acquired color vision changes can indicate optic neuritis (often the first sign of multiple sclerosis), compressive optic nerve lesions, retinal disease, or glaucoma progression. Changes from a previous baseline are particularly significant.
Establishing a baseline color vision status at the initial visit allows future comparisons. If a congenital deficiency is documented early, any subsequent change is clearly acquired and warrants investigation. Without a baseline, distinguishing congenital from acquired deficiency can be difficult.
Normal result
Color vision: Ishihara 14/14 OU (plates 1-14 correct, binocular)
Abnormal result
Color vision: Ishihara OD 8/14, OS 9/14 -- red-green deficiency suspected
Monitoring documentation
Color vision: HRR screening plates normal OU. Monitoring for hydroxychloroquine toxicity.
Always document: test used, number correct out of total, which eye(s), and any relevant context (medication monitoring, occupational screening).
Snellen chart technique, notation, and testing protocol.
Cone photoreceptors, macula, and the neural basis of color vision.
Medications that affect color vision and require monitoring.
Browse all CPO and CPOA study topics organized by category.
Color vision deficiency affects approximately 8% of males and 0.5% of females of Northern European descent. The overwhelming majority of cases are congenital red-green deficiencies (protan and deutan types) inherited as X-linked recessive traits. This is why males are affected far more often -- they have only one X chromosome, so a single defective gene causes the condition. Females need defective genes on both X chromosomes to be affected, though they can be carriers.
Ishihara plates are pseudoisochromatic plates that screen specifically for red-green color deficiency. They are the most widely used screening tool but cannot detect blue-yellow (tritan) deficiencies. Hardy-Rand-Rittler (HRR) plates screen for all three types of color deficiency including blue-yellow. HRR plates are preferred when comprehensive screening is needed, especially when monitoring for acquired color vision loss from medications or disease.
Hold the plates at 14-16 inches (about 75 cm from the patient in some protocols, or arm's length) under good, natural or daylight-balanced illumination. Present each plate for no more than 3 seconds -- spending too long allows patients to use tracing strategies that bypass the intended color discrimination test. Each eye should be tested separately. The patient reads the numbers or traces the paths they see on each plate.
Congenital color vision deficiency cannot be cured. Special tinted lenses (like EnChroma) may enhance color discrimination for some individuals by selectively filtering wavelengths, but they do not restore normal color vision and do not help everyone. Acquired color vision loss may improve if the underlying cause (medication toxicity, optic nerve disease) is treated. The clinical value of screening is identification and documentation, not treatment.
Acquired color vision deficiency can result from medications (ethambutol, hydroxychloroquine, digoxin), optic nerve disease (optic neuritis, compressive lesions), retinal disease (macular degeneration, diabetic retinopathy), cataracts (which preferentially absorb blue light), or toxic exposures. Acquired deficits are often asymmetric (different between the two eyes) and may involve blue-yellow discrimination, unlike congenital deficits which are typically symmetric and red-green.